Jorge del-Toro-Cervera

Prof. Jorge del-Toro-Cervera

MD PhD

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FGFrancisco Galeano-Valle
Francisco Galeano-Valle
LOLucia Ordieres Ortega
Lucia Ordieres Ortega
COCrhistian-Mario Oblitas
Crhistian-Mario Oblitas
JDJorge del-Toro-Cervera
Jorge del-Toro-Cervera
LALuis Antonio Alvarez-Sala-Walther
Luis Antonio Alvarez-Sala-Walther
Pablo Demelo‐RodríguezPablo Demelo‐Rodríguez
Pablo Demelo‐Rodríguez
The relationship between inflammation and venous thrombosis is not well understood. An inflammatory response may be both the cause and consequence of venous thromboembolism (VTE). In fact, several risk factors of VTE modulate thrombosis through inflammatory markers. Acute pulmonary embolism (PE) is burdened by a remarkable mortality rate, up to 34% in severely ill patients presenting with hemodynamic instability. Initial mortality risk stratification is based on hemodynamic instability. Patients with a situation of hemodynamic stability require immediate further risk assessment based on clinical, imaging, and circulating biomarkers, as well as the presence of comorbidities. Some inflammatory biomarkers have shown potential usefulness in the risk stratification of patients with VTE, especially acute PE. C-reactive protein on admission is associated with 30-day mortality and bleeding in VTE patients. P-selectin is associated with right ventricle dysfunction in PE patients and might be associated with VTE recurrences and the extension of thrombosis. Tissue factor microparticles are associated with VTE recurrence in cancer-associated thrombosis. Other inflammatory biomarkers present scarce evidence (inflammatory cytokines, erythrocyte sedimentation rate, fibrinogen, leukocyte count). In this manuscript, we will review the prognostic role of different inflammatory biomarkers available both for clinical practice and research in VTE patients.

1 December 2016 in Revista Clínica Española
Verified
Journal Article
Closed access
JDJorge del-Toro-Cervera
Jorge del-Toro-Cervera
Pablo Demelo‐RodríguezPablo Demelo‐Rodríguez
Pablo Demelo‐Rodríguez